Aims: Significant differences between dogs and humans have been observed in the concentrationQTc effect relationship of compounds with known pro-arrhythmic properties. These findings suggest that interspecies differences must be considered when evaluating drug effects. The aim of this study was to evaluate the performance of model-based approach to assess the risk of QTc prolongation for three investigational compounds (NCE01, NCE02 and NCE03).
Introduction
Assessment of the propensity for QT/QTc interval prolongation is a mandatory step in drug development owing to its supposed prognostic value for the risk of fatal supraventricular arrhythmia [1] . Often the pharmacological mechanism underlying drug-induced QT prolongation is a disturbance in the complex cardiac ion current, and more specifically, inhibition of the human ether-a-go-gogene (hERG)-mediated K + current [2, 3] . Given the potential safety implications of QT/QTc prolongation, an increase ≥ 10 ms has been defined as the acceptable threshold for safety [4, 5] .
However, little effort has been made to establish how such a threshold relates to the real risk of proarrhythmic events in patients or whether similar levels ought to be considered for the evaluation of drug-induced effects in preclinical species.
Undoubtedly, prediction of the propensity for QT/QTc prolongation remains a major milestone in the preclinical drug development, because it would be desirable to discard compounds which are likely to show clinically relevant QTc interval prolongation in humans. In fact, during the screening of candidate molecules, the beagle dog is the most common species used for the in vivo evaluation of safety pharmacology. This choice is based on the supposed similarity in the electrophysiology of the heart in dogs and humans [6] . However, little is known in quantitative terms about the sensitivity and specificity of these labour-intensive experiments [7] . In a recent investigation, we have shown significant differences in the concentration-effect relationships of moxifloxacin, d,l-sotalol and cisapride between dogs and humans [8] . Multiple factors can be considered that explain the translational gap between preclinical species and humans, including differences in heart rate, circadian variation and tissue receptor density [9, 10] . Despite such differences, we have proposed the use of a model-based approach for the evaluation of concentration-effect relationships as the basis for the extrapolation between preclinical species and humans [11] [12] . Pharmacokineticpharmacodynamic (PKPD) modelling offers the possibilities: (i) to correlate drug exposure with QT effect; (ii) to quantify interspecies differences in pro-arrhythmic activity and (iii) most importantly, to assess the liability for QT prolongation (i.e. the probability of ≥ 10-ms increase of QT/QTc interval).
In fact, the use of modelling as an alternative approach to the intersection union test, currently recommended by the ICH-E14 guideline, has been gaining wide scientific recognition. One of the first examples of the approach is illustrated by Friberg et al. who described the delayed effects of citalopram on QTc interval following overdoses [13, 14] . Ollerstam et al . also derived a model to describe the effect of dofetilide and placebo on the QTc interval in conscious telemetered dogs [15] .
More recently, Tsong et al. applied a linear concentration-response model to moxifloxacin and eight test drugs [16] . The investigation revealed some weaknesses in the prediction of the maximal QTc interval change, but suggested the possibility for improved estimates if more robust models are considered. In this context, we would like to emphasise the potential advantages of Bayesian hierarchical models for the characterisation of concentration-effect relationships in early drug development. In conjunction with suitable parameterisation, Bayesian methods allow formal incorporation of prior knowledge during parameter estimation procedures. The model proposed previously for the assessment of the liability for QT/QTc interval prolongation was based on a clear distinction between drug-and system-specific parameters [11] . Such a distinction ensures that drugspecific properties are disentangled from experimental and species-related variability [8, 11] .
Moreover, any knowledge about system-specific parameters (e.g. from past experiments) can be introduced as prior distributions to inform parameter estimation, increasing the precision of estimates, especially when small sample sizes are used.
A natural question that arises from the findings described so far is: are the differences in the PKPD relationships observed between dogs and humans systematic or not? Evidence of systematic differences would enable one to consider the use of an allometric or correlation factor to predict drug effects in humans based on experimental data in dogs. Although differences may exist in baseline function, and receptor densities may vary, it can be anticipated that such a correlation might be used to reflect the underlying mechanisms associated with QTc interval prolongation in vivo [17] . This point is particularly relevant for compounds with known activity on different ion channels, for which in vitro experiments cannot provide an accurate estimate of the drug effects in vivo [18] [19] [20] .
The objective of the present investigation was therefore to assess the value of in vivo safety pharmacology protocols in dogs to predict the liability for QTc interval prolongation of new compounds in humans. A selection of three compounds with different safety pharmacology profiles was included in the analysis to assess the sensitivity of the approach to detect drug effects for compounds that show low or borderline QTc interval-prolonging effect. Ultimately, we aim to explore the feasibility of a wider use of this Bayesian PKPD modelling approach to support decisionmaking during the screening of candidate molecules in early drug development.
Methods

Experimental data
Data from three compounds in development were provided by the participating partners in the TIPharma consortium (http://www.tipharma.com). They are coded as NCE01, NCE02 and NCE03 and have been selected based on the primary objective of this investigation, i.e., to explore the sensitivity of the approach for compounds that show no effect, low or borderline QTc interval prolonging effect.
Preclinical protocols
A four-way crossover design was used for the evaluation of QTc-interval in conscious, freely moving beagle dogs. All dogs were chronically instrumented with radio telemetry probes measuring blood pressure (BP), electrocardiogram (ECG) and body temperature (T). The ECG electrodes were placed in a lead II position. Animals were administered vehicle, a sub-therapeutic, a therapeutic and a supra-therapeutic oral dose of each compound. All experiments were approved by the ethical committees and performed under Good Laboratory Practice (GLP) regulations. Further details on the experimental design and data acquisition are summarised in Table 5 .1A.
Clinical protocols
All three of the clinical protocols were phase I studies in healthy volunteers. The NCE02 and NCE03 data were extracted from randomized, double-blind, placebo-controlled study designs. For NCE02, subjects received either one placebo dose or one active oral treatment. For NCE03, each subject received one placebo dose and one to four oral doses of the active treatment. All studies were performed in accordance with the Declaration of Helsinki and its subsequent revisions. Further details about the experimental design and data acquisition are summarised in Table 5 .1B. 
In vivo preclinical protocols in dogs
The analyses of plasma samples for NCE01 and NCE02 were performed at Drug Metabolism and Pharmacokinetics (DMPK), AstraZeneca R&D Södertälje, Sweden, whereas NCE03 was analysed at Drug Metabolism and Pharmacokinetics (DMPK), GlaxoSmithKline R&D, Ware, UK. The bioanalysis was performed in accordance with GLP using a method based on protein precipitation and liquid chromatography tandem mass spectrometry (LC-MS/MS). Sampling times are listed for each study in Table 5 .1.
Clinical studies in healthy subjects
Drugs were administered in ascending doses as usually performed in phase I studies. Blood samples for pharmacokinetics were drawn from a forearm directly into Vacutainer tubes with K2-EDTA and centrifuged within 30 minutes from collection for 10 minutes at 4°C at 1500g. The plasma was then frozen at -20°C. For NCE01 and NCE02 blood samples were left to clot at room temperature. After clot retraction occurred, samples were centrifuged at 4°C at 1500g for 10 minutes with the minimum of delay. Serum (~1 mL) was carefully pipetted into prelabelled Nunc 1.8 mL polypropylene tubes and then frozen in an upright position at -20°C until assay. All samples were kept frozen in Cardice pellets during transit and transport to various analysis facilities. Compounds were analysed using liquid chromatography and electro-spray tandem mass spectrometry (LC-MS/MS).
Electrocardiographic monitoring and sampling
In vivo preclinical protocols in dogs
Telemetric recordings of the ECG were performed in conscious dogs [15, 21] . In brief, dogs were implanted with a telemetric transmitter under general anaesthesia. The transmitter was placed in the peritoneal cavity, and electrodes were placed in lead II configuration. The sensor catheter was implanted into the femoral artery. Telemetric transmitters were implanted at least 10 days before start of recording and during this time, all dogs were trained for the experimental conditions.
A Latin-square crossover design was used for the experiments, where each animal received each dose of the active compound and placebo at least 3 days apart. ECG (lead II) was recorded in a continuous fashion from 1 h pre-dose to 24 h post-dose. The data were recorded and analysed using the Notocord data acquisition system (HEMsoftware, Notocord Inc., Croissy-sur-Seine, France). The
Dataquest Open ART™ software (St. Paul, MN, USA) was then used to set up and calibrate the telemetry systems. The QT interval duration was measured for every wave complex. An average of five consecutive wave complexes were used in the final analysis. The placement of the ECG calipers was checked and manually corrected if deemed necessary. Individual correction methods for the QTc interval were applied in the final dataset for NCE01 [22] , whereas Van de Water correction factor was used for NCE02. In spite of the different methods used to correct for heart rate, the RR intervals were within the 400-1300 ms range where both methods show acceptable performance according to Ollerstam et al. [22] . Yet, for the current PKPD analysis the corrected QT values were used only for visual checking purposes.
Clinical studies in healthy subjects
The clinical protocols were based on a randomized, double-blind, placebo controlled study design.
All studies were performed in accordance with the ethical principles that have their origin in the were not allowed during the trial, whereas strenuous physical activity was prohibited within 7 days before dosing until completion of the trial. All meals were nutritionally standardized and served at the time of dosing, 4, 6, 9 and 12 h after drug administration. ECG was collected during resting conditions with the subjects in a supine position for several minutes prior to the measurements. Vp, volume of distribution for the peripheral compartment. *CL and V parameters were obtained using individual data fitting in WINNONLIN 4.2.
Pharmacokinetic-pharmacodynamic modelling
Although the same PKPD model was used to describe the effect of the drug on QT/QTc interval, each drug was analysed separately. A Bayesian adaptation of a hierarchical model previously described
Chain and Dubois et al. [8] was used. The model is comprised of three components, including an individual correction factor for RR interval (heart rate), an oscillatory component describing the Cambridge, UK) using the slope and an inter-individual correction factor for gender differences at the following concentrations: 50, 200, 400, 600, 800, 1000, 1200, 1400, 1600, 1800, 2000, 2500, 3000, 3500, 4000, 6000, 7000, 9000, 10 000, 15 000, 30 000, 60 000, 100 000, 120 000, 130 000, 140 000, 150 000, 160 000 nM. The concentration values were chosen in such a way that data points spread across the sigmoid curve.
where 0.00001 is set as an arbitrary small number to avoid computational errors associated with numerical difficulties (i.e. division by zero), F(Gender) is the gender specific population estimate for the baseline QTc interval (QTc0). 5 and 10 ms refers to the QTc interval prolongation threshold of interest, C is the drug concentration, and slope is the QT increase per unit drug concentration.
Results
Pharmacokinetic modelling
The time course of drug concentrations in plasma was characterised for each compound separately, using nonlinear mixed effects modelling where possible or deconvolution techniques. A summary of the pharmacokinetic models and final parameter estimates is shown in Tables 5.2 
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A Dogs
Parameters
- - - - Q [L/h] -
Figure 5.1. Pharmacokinetic analysis for conscious dogs (left) and healthy subjects (right). The lines represent the regression for the population prediction using the model parameters. Dots show the observed concentration data on the corresponding time intervals.
A) NCE01: (upper panel) individual observed concentrations vs. time for a typical subject and (lower panel) observed population median concentrations vs. time; symbols depict different dose levels: ○ and _ _ _ _ for 2.15mg/kg, and ----for 4.3mg/kg in conscious dogs, and and _ _ _ _ for 10mg, + and ----for 30mg, x and -
Pharmacokinetic and pharmacodynamic modelling
The analysis was performed using the recorded ECG measurements and predicted drug concentrations at the corresponding time of sampling. If model parameters could not be estimated accurately, concentrations were imputed by deconvolution techniques, as indicated above. In most cases, system-specific parameters, i.e. baseline QT (QTC0), the QT-RR correction factor (α), the amplitude (A) and phase (Ф) showed values within the same range within each species. Small differences were found in QTc0 in dogs due to a possible age difference between the studies. In addition, the observed variation in A and Ф could be explained by different sampling schemes used in each experimental protocol. As shown in Table 5 .4, however, the main difference was found in the drug-specific parameter (slope), which varied significantly both across compounds and between dogs and humans.
In addition to the typical Bayesian criteria for parameter convergence and model acceptance [24] [25] [26] [27] , goodness-of-fit plots were generated for each compound and summarised in Figure 5 .2. In principle, the larger the positive value of the slope, the stronger the effect of the drug on the QTc interval. Drugs showing slope value around zero will produce no effect or borderline effect on QTc interval. Eventually, estimation of negative values for the slope indicates a possible shortening effect on the QT/QTc interval. Hence, our findings corroborate the sensitivity of the method to assess the pro-arrhythmic properties of molecules with minor or no QT prolonging effects. NCE01 can be considered a QTc-prolonging compound, whereas NCE02 appeared to have QT shortening
properties. No clear effects on QTc interval were observed after administration of NCE03, because the maximal probability reached only 0.3. Such an estimate suggests that some pro-arrhythmic activity may be present, but it is not pronounced enough to result in QTc prolongation ≥ 10 ms. In fact, this borderline effect is demonstrated by the higher probability values obtained when a threshold of ≥ 5ms was used. The estimated probability at peak concentrations of the QT interval prolongation and the corresponding PKPD parameters are summarised in Table 5 .4. α, individual heart rate correction factor; ϕ, phase of the circadian rhythm; A, amplitude; BSV, between-subject variability; Cmax, peak concentration; OCC, occasions. *29 healthy subjects received multiple dose levels, but dosing events were treated as different individuals for the purposes of the analysis. In this study, we have shown the application of a Bayesian hierarchical model to describe the relationship between drug concentration and QTc interval prolongation for three new compounds in conscious dogs and their correlation with the pharmacological effects in humans at comparable exposure ranges. As indicated in our initial publication [8] , the availability of a common model to assess drug effects in dogs and humans and the explicit distinction between drug-and systemspecific parameters allow direct inferences to be made about the probability of drug-induced QTc interval prolongation in human. Moreover, these results appear to confirm our earlier findings with d,l-sotalol, cisapride and moxifloxacin, in that dogs are apparently less sensitive to QT/QTc prolongation than humans [8] . These differences are evident when comparing the estimated slope values and the corresponding liability for QT/QTc interval prolongation, expressed as probability of increase ≥ 10 ms. In addition, these findings suggest that the model parameterisation is robust
enough not only to demonstrate significant and no drug effects (i.e. true positive and true negative results), it also detects adverse changes such as QT shortening.
It was also evident from the analysis, that accurate interpretation of the preclinical findings requires some knowledge about the expected therapeutic range, which was expected to be known given the range of doses selected for the phase I studies. Currently, based on preclinical results it is not possible to quantify fully the liability for QT/QTc interval prolongation in humans without some certainty about the clinically relevant levels. Inferences from extremely high dose levels, often used in toxicology experiments may lead to biased conclusions about the magnitude of the effect on QTc interval and its clinical implication. In addition, we recommend that a lower threshold is evaluated when probability values between 0.1 and < 0.5 are observed for exceeding ≥ 10 ms, In this way, it is possible to assess the magnitude of potential pro-arrhythmic effects for compounds with borderline activity, as shown for NCE03.
We acknowledge that the evidence from three compounds with unknown mechanisms of action is not sufficient to establish the sensitivity and specificity of the method. These results provide, however, further motivation to explore the feasibility of using a conceptual framework for future evaluation of the pro-arrhythmic potential of candidate molecules, in which drug specific parameters are used to scale up or translate the effects observed in dogs [17] . The approach consists in the use of simulation scenarios in which pharmacokinetic profiles in humans are simulated taking into account the putative drug effects, as defined by the drug-specific parameter in our model (i.e. slope). In addition, it should be noted that based on the current parameterisation, it is possible to evaluate the pro-arrhythmic effects of a drug also from a medical perspective, for instance to assess correlations between drug exposure and abnormal or extreme QT values. In this context one could generate, for example, probability curves for observing QT intervals > 500 ms.
From a drug development perspective, our approach appears to overcome one of the main limitations of earlier PKPD models in preclinical research, i.e. their use as a screening tool in early drug development. Usually different PKPD models are required to describe preclinical and clinical data. In other cases, additional in vitro data have been used to correlate findings across species [9, 15, 28] . Furthermore, the choice of parameterisation in these analyses does not allow for the reuse of the model for a different compound or compound class, defeating the main purpose of such an analysis.
The proposed approach also prevents some of the pitfalls from inaccuracies in current experimental protocols [29] . Although some criticism may be made regarding the lack of a more mechanistic parameterisation of the effects on repolarisation, the use of a slope provides a strong basis for the generalisability of the approach, irrespective of the underlying receptor-ligand interaction [30, 31] . In terms of sensitivity and specificity, we anticipate another important advantage over current drug screening strategies, which rely on the identification of molecules with low potency hERG blocking activity whilst retaining desirable therapeutic properties. In fact, our results raise questions about the predictive value hERG safety margins, which are currently used in conjunction with in vivo nonclinical data to establish the liability for QT/QTc interval prolongation in humans [2] .
Experimental design requirements
The pharmacokinetic data used as input for the assessment of the PKPD relationships were derived taking into account between subject variability in drug exposure and assuming that any effects were associated with the parent drug, rather than with potential metabolites. It should be highlighted that despite the possibility of mean or typical population data when describing pharmacokinetics, overlooking variability in drug disposition may lead to biased conclusions about a compound's liability for QT/QTc interval prolongation. It is therefore essential that individual predicted concentrations are used. This imposes a slightly different experimental protocol than what is typically done in safety pharmacology, i.e., drug exposure is imputed from satellite animals in other toxicology protocols, where pharmacokinetic sampling is required. It should be recognised that individual pharmacokinetic profiles may be effective in disentangling spurious noise from the large inter-and intra-individual variability in ECG recording [32] . In addition, the availability of individual concentration vs. time profiles provides further insight into the role of other moieties, such as metabolites, in the onset and maintenance of effects
With regard to the use of empirical sampling schemes, we have highlighted in a previous publication that the choice for limited or sparse sampling (usually three to eight samples) without clear understanding of the pharmacokinetic properties in the species of interest renders the assessment of PKPD relationships rather difficult and imprecise. Optimal design concepts should be used to prevent or overcome these issues [8, 33, 34] . Sampling matrices can also be considered in which some blood samples are collected during ECG monitoring and additional samples are taken on a separate occasion after or before the actual safety experiment.
Prediction of QT/QTc interval in humans
The ultimate goal of this research project is to evaluate the feasibility of translating drug effects in conscious dogs to humans in terms of a decision algorithm. Such an algorithm should allow one to establish the liability for QT/QTc interval prolongation and consequently determine whether or not a compound should progress in development or be terminated. Currently, neither the use of a thorough QT study in late clinical development nor the exclusion of molecules with hERG channel affinity during drug screening are appropriate filters for decision making purposes. Thorough QT studies have been shown to be highly cost ineffective, whereas relying on hERG binding findings at experimental exposure levels that may not be clinically relevant creates unnecessarily high attrition rates.
Undoubtedly, there are many complexities in trying to establish interspecies correlations, particularly when compounds show multiple binding sites and/or metabolites are shown to have ion channel inhibitory properties [35, 36] . In these cases, the solution is possibly to investigate further the underlying causes of torsade de pointes, with the aim of being able to predict torsade de pointes, rather than using an imperfect surrogate marker, i.e., QTc interval prolongation [29] . As long as such a marker is not available, it seems obvious that fit-for-purpose protocols are needed that enable the characterisation of the underlying PKPD relationships.
Conclusion
In summary, NCE01, NCE02 and NCE03 have shown distinctive pro-arrhythmic activity, with QTc prolongation, no and borderline QT-prolonging effects, respectively. The PKPD relationships were successfully described by a single structural model with acceptable precision in prediction. The probability of an increase in QT/QTc interval ≥ 10 ms was evident for NCE01, whilst this threshold was not achieved for NCE02 and NCE03 in either species. Together with the evidence of model performance for compounds with known pro-arrhythmic effects, our approach seems to offer the basis for accurate safety screening of novel molecules. Most importantly, the method can be implemented easily within pharmaceutical Research and Development.
